BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28939017)

  • 1. The rise of biosimilars: How they got here and where they are going.
    Patel D; Gillis C; Naggar J; Mistry A; Mantzoros CS
    Metabolism; 2017 Oct; 75():45-53. PubMed ID: 28939017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars in the Treatment of Retinal Disease in the United States.
    Vakharia PS; Eichenbaum DA; Baumal CR
    Ophthalmic Surg Lasers Imaging Retina; 2023 Jun; 54(6):362-366. PubMed ID: 37222553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities and challenges in biosimilar uptake in oncology.
    Dolan C
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current market and regulatory landscape of biosimilars.
    Bhatt V
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
    Endrenyi L; Markus R
    J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in Dermatology: Current Situation (Part I).
    Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
    Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.